{{Rsnum
|rsid=1158392
|Chromosome=2
|position=75483619
|Orientation=minus
|GMAF=0.2938
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 75.2 | 21.2 | 3.5
| HCB | 27.9 | 46.3 | 25.7
| JPT | 16.8 | 44.2 | 38.9
| YRI | 42.2 | 47.6 | 10.2
| ASW | 38.6 | 50.9 | 10.5
| CHB | 27.9 | 46.3 | 25.7
| CHD | 23.9 | 57.8 | 18.3
| GIH | 68.3 | 23.8 | 7.9
| LWK | 52.7 | 38.2 | 9.1
| MEX | 53.4 | 44.8 | 1.7
| MKK | 47.7 | 43.2 | 9.0
| TSI | 78.4 | 20.6 | 1.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1158392
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.22, combined P value= 4.02E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470239
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1158392
|overall_frequency_n=29
|overall_frequency_d=128
|overall_frequency=0.226562
|n_genomes=22
|n_genomes_annotated=0
|n_haplomes=26
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}